Trial Profile
Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Biotin (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms MS-SPI
- Sponsors MedDay Pharmaceuticals
- 02 Apr 2022 Status changed from active, no longer recruiting to completed.
- 12 Oct 2018 Results from the extension phase of the study presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
- 28 Oct 2017 Results of a sub-group analysis assessing the effect of MD1003 in spinal progressive multiple sclerosis, presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis